Sarcoidosis led to thrombotic microangiopathy (TMA), a rare blood disorder, and associated severe kidney damage and blood-related abnormalities in a 31-year-old man, a case study reported. This rare case emphasizes the importance of considering sarcoidosis in uncommon cases of multiple organ dysfunction, as well as early intervention by a…
People with sarcoidosis who live in neighborhoods lacking economic and social resources have lower lung function and faster lung function decline, a study in the U.S. and Canada revealed. Non-white patients were overrepresented in the group with greater disadvantage, suggesting how race and differences in socioeconomic status can lead…
Xentria has raised $25 million in funding to further the development of XTMAB-16, its experimental antibody therapy for sarcoidosis. The funding will allow for the launch of a global clinical trial of XTMAB-16 in sarcoidosis patients, planned to start early next year. “I am excited about this…
About 35 out of every 100,000 people with private insurance in the U.S. are estimated to have sarcoidosis, and most disease clusters are located near urban areas on the East Coast, a new study shows. However, most of these clusters disappeared when controlling for race, “suggesting that geographical racial…
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…
Protalix Biotherapeutics and SarcoMed USA have entered into an exclusive worldwide license agreement to advance PRX-110 (alidornase alfa) as a treatment of pulmonary sarcoidosis and other respiratory diseases. “Most patients with pulmonary sarcoidosis do not show symptoms and do not realize they have the disease until it has…
Corticosteroids, a type of anti-inflammatory medication, is the most-prescribed treatment for people with sarcoidosis, a study in a U.S. population shows. Also, the study found, a small percentage of these patients are receiving biological therapies (those using compounds derived from living organisms), despite not being approved in…
Get regular updates to your inbox.